Odpornost bakterij v svetu in pri nas

doc. dr. Mateja Pirš, dr.med.

Laboratoriji:

- Inštitut za mikrobiologijo in imunologijo, Medicinska fakulteta v Ljubljani
- Nacionalni laboratorij za zdravje, okolje in hrano:
  - Maribor
  - Celje
  - Murska Sobota
  - Kranj
  - Koper
  - Nova Gorica
  - Novo Mesto
- Splošna bolnišnica:
  - Franca Derganca Nova Gorica
  - Slovenj Gradec
- Univerzitetna klinika za pljučne bolezni in alergijo Golnik

- EARS–Net ECDC 2018:
  - države EU
  - 8 vrst, invazivni izolati
- SKUOPZ poročila 2017
  - Slovenija,
  - 19 bakterijskih vrst, vse klinične kužnine

- CEASAR - Central Asian and Eastern European Surveillance of Antimicrobial Resistance
- Antimicrobial Resistance Global Report on Surveillance, WHO 2018

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija



Staphylococcus aureus

S.aureus



MRSA



Vir: SKOUPZ 2017

Staphylococcus aureus - MRSA

Lokalni podatki



EARS-Net/CAESAR 2018



EU/EEA 2018: ↓16,4 %

EU/EEA 2015: 19,0%

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija
SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz





Pirš M in sod. Vzorci občutljivosti za antibiotike in odpornosti proti njim pri MRSA v dveh slovenskih regijah v obdobju 2011–2015. Likarjev simpozij 2016



Pirš M in sod. Vzorci občutljivosti za antibiotike in odpornosti proti njim pri MRSA v dveh slovenskih regijah v obdobju 2011–2015. Likarjev simpozij 2016

World Health Organization

Antimicrobial resistance: global report on surveillance. 2014

Table 7 *Staphylococcus aureus:* **Resistance to beta-lactam antibacterial drugs (i.e. methicillin-resistant *S. aureus*, MRSA)**

Data sources based on at least 30 tested isolates[a]	Overall reported range of resistant proportion (%)	Reported range of resistant proportion (%) in invasive isolates[b] (no. of reports)
African Region		
– National data (n=9 countries)	12–80	52 (n=1)
– Publications (n=27) from 10 additional countries	0–100	33–95 (n=3)
Region of the Americas		
– National data or report to ReLAVRA (n=15 countries)	21–90	
– National networks (n=2) no additional country	21–84	
– Publications (n=17) from 7 additional countries	2.4–90	43–45 (n=2)
Eastern Mediterranean Region		
– National data (n=4 countries)	10–53	53 (n=1)
– Hospital network[c] (n=1) from 1 additional country	46	
– Publications (n=31) from 10 additional countries	0–92	13–18 (n=3)
European Region		
– National data or report to EARS-Net n=36 countries)	0.3–60	0.3–6 (n=32)
– Publications (n=5) from 2 additional countries	27–80	27–50 (n=3)
South-East Asia Region		
– National reports (n=3 countries)	10–26	
– Publications (n=25) from 4 additional countries	2–81	37 (n=1)
Western Pacific Region		
– National data (n=16 countries)	4–84	
– Institute surveillance (n=2 from one additional country)	1–4	
– Publications (n=1) from one additional country	60	

Proti vankomicinu odporni enterokoki (VRE)
Enterococcus faecium- VRE

Lokalni podatki



EARS-Net/CAESAR 2018



EU/EEA 2018: ↑17,3%

EU/EEA 2015: 10,5%

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija
SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



Proti penicilinu odporni *S. pneumoniae* (PNSP)



Vir: SKOUPZ 2017

Proti penicilinu odporni *S. pneumoniae* (PNSP)

Lokalni podatki



EARS-Net 2018



EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija
SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



World Health Organization

Antimicrobial resistance: global report on surveillance. 2014

Table 8 *Streptococcus pneumoniae*: Resistance or non-susceptibility to penicillin

Data sources based on at least 30 tested isolates	Overall reported range of proportion resistant (R) and/or non-susceptible (NS)	Reported range of proportion resistant or non-susceptible in invasive isolates[a] (no. of reports)
African Region – National data (n=5 countries) – Publications (n=16) from 14 additional countries	 3–16 (R) or 57–60 (NS) 1–100 (R) or 9–69 NS or 0–79 [b]	 3 (R) (n=1) 9–18 (NS) or 24–79 [b] (n=5)
Region of the Americas – National data or report to ReLAVRA or SIREVA (n=15 countries) – Publications (n=1) from 1 additional country	 0–48 [b] 53 (non-meningitis) (NS)	 0–48 [b] (n=14) 64 (meningitis) (NS)
Eastern Mediterranean Region – National data (n=3 countries) – Publications (n=17) from 9 additional countries	 13–34 (R) or 5 (NS) 0.3–64 (R) or 17–48 (NS) or 0–93 [b]	 34 (R) (n=1) 2–14 (R) or 17–40 (NS) (n=10)
European Region – National data or report to EARS-Net (n=31 countries) – Publications (n=1) from 1 additional country	 0–61 (R) or 0.9–73 (NS) 13–68 (NS)	 0.9–61 (NS) or 32–45 [b] (n=27) 13 (NS) (n=1)
South-East Asia Region – National data (n=2 countries) – Publications (n=2) from 2 additional countries	 47–48 [b] 0–6 (R)	 0 (R) (n=1)
Western Pacific Region – National data (n=10 countries) – Hospital data (two hospitals in 1 country) – Publications (n=4) from 2 additional countries	 17–64 (NS) or 0–47 [b] 0–2 44–96 (R) or 0–69 (NS)	 44 (R) or 0 (NS) (n=2)

Mycobacterium tuberculosis

- Večkratno odporni sevi so velik svetovni problem, v Sloveniji jih ni!
- Občutljivost vseh ključnih zdravil že nekaj let od 97 do 100 %.

Streptococcus pyogenes

- Občutljivost za penicilin 100 %
- Občutljivost za eritromicin 94 %, za klindamicin 96 %.

Figure 15 Proportion of new TB cases with multidrug resistance (MDR-TB) worldwide[a]



Numbers are based on the most recent year for which data have been reported, which varies among countries.

Salmonella spp.

- Prevladujoči serovari!
- ↓ občutljivega serovara *S*. Enteritidis,
- Δ občutljivost predvsem za ciprofloksacin.

Table 9 Nontyphoidal *Salmonella*: Resistance to fluoroquinolones[a] (summary of reported or published proportions of resistance, by WHO region)

Data sources based on at least 30 tested isolates	Overall reported range of resistant proportion (%)	Reported range of resistant proportion (%) in blood isolates (no. of reports)
African Region – National data (n=9 countries) – Publications (n=11) from 8 additional countries	 0–35 0–30	 0–30 (n=4)
Region of the Americas – National data (n=13 countries) – Publications (n=1) from 1 additional country	 0–96 0	
Eastern Mediterranean Region – National data (n=4 countries) – Publications (n=4) from 4 additional countries	 2–49 0–46	 6 (n=1)
European Region – National data or report to FWD-Net, (n=29 countries) – Publications (n=1) from1 additional country	 2–3 13	
South-East Asia Region – National data (n=2 countries) – Publication (n=1) from 1 additional country	 0.2–4 1.4	
Western Pacific Region – National data (n=9 countries) – Network/institution data (n=4 from 2 countries) – Publications from remaining countries (n=0)	 0–14 0–0.3	



Campylobacter jejuni

- Slaba občutljivost za ciprofloksacin 25 %
- Dobra občutljivost za eritromicin >99 %
- Podobno velja za *C. coli*

- Posamezni večkratno odporni izolati, odporni proti vsem antibiotikom, ki jih je po EUCAST mogoče testirati:

  CIP R + ERI R + TET R.



Neisseria gonorrhoeae

Table 11 *Neisseria gonorrhoeae*: decreased susceptibility to third-generation cephalosporins[a]

Data sources based on at least 30 tested isolates	Overall reported range of proportion with decreased susceptibility (%)
African Region – National data and/or GASP data (n=2 countries) – Publications (n=5) from 5 additional countries	 0–12 0
Region of the Americas – National data and/or GASP/ GISP data (n=4 countries) – Publications from remaining countries (n=0)	0–31
Eastern Mediterranean Region – National data and/or GASP data (n=2 countries) – Publications (n=1) from 1 additional country	 0–12 0
European Region – National data and/or EURO-GASP/GRASP data (n=17) – Publications (n=3) from 3 additional countries	 0–36 0
South-East Asia Region – National data and/or GASP data (n=5 countries) – Publications from remaining countries (n=0)	 0–5
Western Pacific Region – National data and/or GASP data (n=12 countries) – Publications from remaining countries (n=0)	 0–31



Escherichia coli

E.coli



E.coli - ESBL



Vir: SKOUPZ 2017

Escherichia coli - ESBL

Lokalni podatki



EARS-Net/CAESAR 2018



Escherichia coli - ESBL

Lokalni podatki



EARS-Net/CAESAR 2018



EU/EEA 2018: ↑15,1 %

EU/EEA 2015: 14,6%

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija

SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



- Švedska - Nosilstvo ESBL v skupnosti / pri bolnikih z invazivnimi okužbami.

- Zdravi nosilci, kolonizirani z ESBL 4,7 %; večinoma malo patogeni sevi;
- Invazivne kužnine - prevladuje ST 131.

Journal of Antimicrobial Chemotherapy Advance Access published October 24, 2016

J Antimicrob Chemother
doi:10.1093/jac/dkw419

Journal of Antimicrobial Chemotherapy

Community carriage of ESBL-producing *Escherichia coli* is associated with strains of low pathogenicity: a Swedish nationwide study

Sofia Ny[1,2], Sonja Löfmark[1], Stefan Börjesson[3], Stina Englund[3], Maj Ringman[1], Jakob Bergström[1], Pontus Nauclér[4,5], Christian G. Giske[2,6*] and Sara Byfors[1]

[1]Public Health Agency of Sweden, Stockholm, Sweden; [2]Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Stockholm, Sweden; [3]National Veterinary Institute, Uppsala, Sweden; [4]Infectious Disease Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; [5]Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; [6]Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden



Figure 1. Distribution of phylogroups, ST131 and H30-Rx among ESBL- and pAmpC-producing *E. coli* isolates from BSI and carriers. Significant differences are marked with an asterisk. See Table 3 for statistical data.

CMR
Journals.ASM.org

Trends in Human Fecal Carriage of Extended-Spectrum β-Lactamases in the Community: Toward the Globalization of CTX-M

October 2013

Paul-Louis Woerther,[a] Charles Burdet,[b,c] Elisabeth Chachaty,[a] Antoine Andremont[b]





World Health Organization

Antimicrobial resistance: global report on surveillance. 2014

Table 3 *Escherichia coli:* Resistance to third-generation cephalosporins[a] (summary of reported or published proportions of resistance, by WHO region)

Data sources based on at least 30 tested isolates[b]	Overall reported range of resistant proportion (%)	Reported range of resistant proportion (%) in invasive isolates[c] (no. of reports)
African Region		
– National data (n=13 countries)	2–70	28–36 (n=4)
– Publications (n=17) from 7 additional countries	0–87	0–17 (n=5)
Region of the Americas		
– National data or report to ReLAVRA (n=14 countries)	0–48	
– Publications (n=10) from 5 additional countries	0–68	
Eastern Mediterranean Region		
– National data (n=4 countries)	22–63	41 (n=1)
– Surveillance network in 1 country[d]	39 (caz)–50 (cro)	
– Publications (n=44) from 11 additional countries	2–94	11–33 (n=6)
European Region		
– National data or report to EARS-Net (n=35 countries)	3–82	3–43 (n=32)
– Publications (n=5) from 2 additional countries	0–8	0–8 (n=2)
South-East Asia Region		
– National data (n=5 countries)	16–68	
– Publications (n=26) from 2 additional countries	19–95	20–61 (n=2)
Western Pacific Region		
– National data (n=13 countries)	0–77	
– Institute surveillance (data from 3 hospitals in one country)	4–14	
– Publications (n=4) from 2 additional countries	8–71	

CMR
Journals.ASM.org

Trends in Human Fecal Carriage of Extended-Spectrum β-Lactamases in the Community: Toward the Globalization of CTX-M

October 2013

Paul-Louis Woerther,[a] Charles Burdet,[b,c] Elisabeth Chachaty,[a] Antoine Andremont[b]



FIG 3 Representation of the main digestive or environmental reservoirs of ESBL-E to which the worldwide human community belongs and is also exposed. Each independent reservoir is included in a dashed black outline, inside which cross-transmission may occur. Arrows show the flux of ESBL-E from one reservoir to another. Environmental niches comprise mainly water, soils, and plants, where genetic material exchanges between bacteria of digestive and/or environmental origin occur.

Znotraj gospodinjstva:

- **Pacient prenese ESBL na 67 % članov gospodinjstva.**
- **Navadno nosilstvo članov ni dolgotrajno.**

Haverkate MR, et al., Quantifying within-household transmission of extended-spectrum b -lactamase-producing bacteria, CMI 2016

Escherichia coli - Cef3G NS + FQ + AG

Lokalni podatki



EARS-Net/CAESAR 2018



Kombinirana odpornost proti 3. gen. cefalosporinov, fluorokinolonov in aminoglikozidov:

- EU/EEA 2015 6,3 % → 2018 6,2 %
- Slovenija 2016 4,7 %

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija

SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



Klebsiella pneumoniae

K. pneumoniae



K. pneumoniae - ESBL



Vir: SKOUPZ 2017

Klebsiella pneumoniae - Cef3G NS

Lokalni podatki



EARS-Net/CAESAR 2018



EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija
SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



Klebsiella pneumoniae - Cef3G NS + FQ + AG

Lokalni podatki



EARS-Net/CAESAR 2018



Kombinirana odpornost proti 3. gen. cefalosporinov, fluorokinolonov in aminoglikozidov:

- EU/EEA 2015 19.7 % → 2018 19,6 %
- Slovenija 2018 10,0 %

Pseudomonas aeruginosa



- Ni večjih sprememb
- Problem so izolati, odporni proti vsem BL antibiotikom (lahko tudi drugim razredom), nekateri izločajo karbapenemaze VIM,
- Občutljivost za protipseudomonasne cefalosporine je boljša kot občutljivost za karbapeneme.

Pseudomonas aeruginosa – 3/5 KRB-TZP-CAZ-FQ-AG R

Lokalni podatki



EARS-Net 2018



EU/EEA 2018: ↓12,8 %

EU/EEA 2015: 15,1%

EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija



Acinetobacter baumannii

- Naraščajoč delež CRAb
- večkratno odporni izolati, ki izločajo karbapenemaze (OXA-40/OXA-23), pogosto odporni tudi proti drugim antibiotičnim razredom
- V več regijah, različno pogosti.



Acinetobacter spp. - CRAb

Lokalni podatki



EARS-Net / CAESAR 2018



EARS-NET SLOVENIJA: http://www.nijz.si/sl/ears-net-slovenija
SKUOPZ: http://www.imi.si/strokovna-zdruzenja/skuopz/skuopz



Klebsiella pneumoniae - CRE

Lokalni podatki



EARS-Net/CAESAR 2018



EU/EEA 2018: ↑7,5 %

EU/EEA 2015: 6,8 %

Klebsiella pneumoniae - CRE



Bolniki s CRE-CPE, SLO 2016

- Število molekularno potrjenih bolnikov s CRE-CPE v Sloveniji - preliminarni neobjavljeni podatki, po mesecih.

- Mateja Pirš, IMI & Andrej Golle NLZOH)

Skupno bolnikov	37
Nadzorne kužnine	25 (67,6)
Klinične kužnine	2 (5,4)
Klinične in nadzorne kužnine	6 (16,2)
Ni podatka	4 (10,8)



1. izbruh CPE

- 40 znanih bolnikov v UKCL
- Okužbe ali kolonizacije s CPE

- 5 bolnikov premeščenih v druge bolnišnice (v štirih regijah)
- vsaj 2 bolnika → prehodna hospitalizacija na negovalnih oddelkih
- 4 → DSO
- Vsaj 2 bolnika → zdravilišče.

kri	urin	Spodnja dihala	Rane/tkivo	Abdominalna /plevralna votlina	črevesje
3 (7,5%)*	10 (25%)	8 (20%)	5 (12,5%)	2 (5%)	36 (90%)*
*2 KPN-OXA48 1 PM-NDM					*21 (52,5%) samo NDZ

Successful control of the first OXA-48 and/or NDM carbapenemase-producing *Klebsiella pneumoniae* outbreak in Slovenia 2014–2016

M. Pirš [a], T. Cerar Kišek [a], V. Križan Hergouth [a], K. Seme [a], M. Mueller Premru [a], S. Jeverica [a], M. Logar [b], T. Mrvič [b], B. Žnidaršič [b], O. Jordan Markočič [c], T. Lejko Zupanc [b,*]

Journal of Hospital Infection 101 (2019) 142–149



Figure 1. Timeline of newly discovered carbapenem-resistant Enterobacteriaceae (CPE)-positive cases during the outbreak.




K. pneumoniae CPE
KPC 5%
VIM 2%
NDM 21%
OXA48 48%
NDM+OXA48 24%
KPC
VIM
NDM
OXA48
NDM+OXA48
21,4
5,1
19,5
5,1
66,7
25,6
73
83,8
92,1
TZP
CAZ
CTX
FEP
ATM
ETP
IMP
MEM
GENTA
AMIKA
CIP
SXT
TGC
CO
KPN-CPE OXA-48 (n=42)
KPN-CPE metaloBL (n=39)

Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

Lancet Infect Dis 2016
Published Online
November 17, 2016

- **E. coli – CRE**:
  - KPC 7,2%, NDM 10,3%, VIM 0%, OXA-48 22,2% (other 60,3%)

ceftazidim/avibactam

- **K. pneumoniae – CRE**:
  - KPC 31,5%, NDM 7,7%, VIM 5,7%, OXA-48 25,8% (other 29,3%)

- **CRE – CPE**:
  - Izolati so običajno XDR – odporni proti BL, FQ, TMP/SXT
  - kolistin 28,3% R
  - fosfomicin: 54% R
  - tigecicline: 5,2% R
  - **Pan-rezistentni izolati: 9,3%**



Klebsiella pneumoniae - CRE



EARS-Net / CAESAR 2005-2018

Odpornost proti karbapenemom pri enterobakterijah in gramnegativnih nefermentativnih bacilih

MALO alternativnih zdravil:

- Usmerjeno zdravljenje → lahko zakasnela uvedba ustreznega antibiotika
- Problem odpornosti → XDR/PDR izolati

„Rezervni“ antibiotiki:

n

- Ceftolozan/tazobaktam (ne CP)
- Ceftazidim/avibactam (ne metaloK)

Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing *Klebsiella pneumoniae* Traced to Clonal Expansion of an *mgrB* Deletion Mutant

Tommaso Giani,[a] Fabio Arena,[a] Guendalina Vaggelli,[b] Viola Conte,[a] Adriana Chiarelli,[a] Lucia Henrici De Angelis,[a] Rossella Fornaini,[c] Maddalena Grazzini,[d] Fabrizio Niccolini,[d] Patrizia Pecile,[b] Gian Maria Rossolini[a,b,e,f]

October 2015 Volume 53 Journal of Clinical Microbiology

TABLE 1 Observed BSI caused by *K. pneumoniae* during the study period[a]

Yr	No. of *K. pneumoniae* BSI	No. (%) of *K. pneumoniae* isolates that were:			
		Carbapenemase sensitive	Carbapenemase resistant[b]	COL^r CRKP[b,c]	Colistin consumption[d]
2009	29	28 (97)	1 (3)	0 (0; 0)	0.004
2010	49	38 (78)	11 (22)*	1 (3; 9)	0.013
2011	76	44 (58)	32 (42)*	4 (5; 12)	0.018
2012	128	46 (36)	82 (64)*	53 (41; 65)*	0.014
2013	93	32 (34)	61 (66)	35 (38; 57)	0.015
Total	375	188 (50)	187 (50)	93 (25; 50)	

[a] Numbers and proportions of BSI cases caused by carbapenem-susceptible, carbapenem-resistant, and carbapenem- and colistin-resistant (COL^r CRKP) strains. For patients with recurrent BSI episodes, only the first episode was considered.

[b] An asterisk indicates that the difference in the proportion of resistant isolates was statistically significantly different ($P < 0.05$) from that for the previous year. For statistical analysis, the chi-squared test with Yates' correction or Fisher's exact test (as appropriate) was used.

[c] Proportions are reported in relation to both *K. pneumoniae* BSI and CRKP BSI. (Values are shown in parentheses and separated by semicolons.) COL^r *K. pneumoniae* was only observed among CRKP cases.

[d] Data on colistin consumption in the hospital during the study period, expressed as the defined daily dose per 1,000 inhabitants per day, are also reported.

World Health Organization

Antimicrobial resistance: global report on surveillance. 2014

Table 6 *Klebsiella pneumoniae:* **Resistance to carbapenems[a] (summary of reported or published proportions of resistance, by WHO region)**

Data sources based on at least 30 tested isolates[b]	Overall reported range of resistant proportion (%)	Reported range of resistant proportion (%) in invasive isolates[c] (no. of reports)
African Region		
– National data (n=4 countries)	0–4	
– Publications (n=0)		
Region of the Americas		
– National data or report to ReLAVRA (n=17 countries)	0–11	
– Publications (n=2) from 2 additional countries	0–2	
Eastern Mediterranean Region		
– National data (n=4 countries)	0–54	54 (n=1)
– Surveillance network[d] (n=1) in 1 additional country	6	
– Publications (n=9) from 5 additional countries	0–21	0 (n=1)
European Region		
– National data or report to EARS-Net (n=31 countries)	0–68	0–68 (n=30)
– Publications (n=3) from 2 additional countries	2–7	2 (n=1)
South-East Asia Region		
– National data (n=4 countries)	0–8	
– Publications (n=15) from 2 additional countries	0–55	0–52 (n=3)
Western Pacific Region		
– National data (n=9 countries)	0–8	
– Institute surveillance (data from 2 hospitals in 1 country)	0–1	
– Publications (n=2) from 2 additional countries	0–11	

Infection Control: Infection control

Importance of introduction of multidrug-resistant organisms to UMC Ljubljana by repatriates and foreign citizens – a 7-year retrospective analysis

M. Pirs[1], T. Lejko Zupanc[2], B. Beovic[3], B. ?nidar?ic[2], M. Mueller Premru[1]

[1]Faculty of Medicine, Institute of clinical microbiology and immunology, Ljubljana, Slovenia ; [2]University Medical Centre, Infection Control Unit, Ljubljana, Slovenia ; [3]University Medical Centre, Department of Infectious Diseases, Ljubljana, Slovenia

Methods: Retrospectiveanalysis of laboratory and patient data was performed for patients that were repatriated from foreign hospitals and foreign citizens treated at UMCbetween 2007 and November of 2013 that were colonized or infected with MDRO.

Results: Intotal, 100 patients, colonized or infected with MDRO, were repatriatesor foreign citizens. In 36 of them (36.0%)colonization or infection with multiple (up to 8) MDRO was noted, 17 (17.0%) were colonized or infected with two,12 (12.0%) with three, 2 (2%) with four, 4 (4.0%) with five MDRO, one patientwas colonized with 8 different MDRO (Table 1).ESBL-producing *Enterobacteriaceae*were founc

Table 1. MDRO isolated from repatriates and foreign citizens in UMC Ljubljana between 2007 to November 2013.

	SA-MRSA	VRE	ESBL	CPE	CRAb	PA – BLNS
No of patients (total)	39	7	62	7	20	6
Clinical samples	24	2	45	3	15	6
blood cultures	2	0	4	0	2	0
surveillance samples	34	6	51	6	11	1

SA-MRSA –methicillin-resistant *S. aureus*, VRE – vancomycin-resistant *E. faecium* or *E. faecalis*, CPE carbapenemase-producing *Enterobacteriaceae*, CRAb – carbapenem resistant *A. baumannii*, PA – BLNS - *P. aeruginosa* nonsusceptible to antipseudomonal betalactam antibiotics

Štrumbelj I. Strokovno srečanje ob Evropskem dnevu antibiotikov 2016: Število smrti zaradi odpornosti mikrobov na leto v Sloveniji - izračun po globalni projekciji UK Review on Antimicrobial Resistance (UK R AMR).





Predpostavka nespremenjenih globalnih trendov ter: izračun UK R AMR velja za vse države enako.
Glede na prebivalstvo, Svet 7.835.639.694, Slovenija 1.978.029 (0,025 %), vir CIA World Factbook.

V Sloveniji umre letno približno 19.000 ljudi.

Illustration of the “discovery void.” Dates indicated are those of reported initial discovery or patent.



Silver L L Clin. Microbiol. Rev. 2011;24:71-109

Kaj lahko naredimo?

- Za **upočasnitev porasta** odpornosti proti antibiotikom in **preprečevanje širjenja** večkratno odpornih bakterijskih klonov z visokim tveganjem za širjenje so bistvenega pomena:
  - **smotrna uporaba antibiotikov**
  - **dobra bolnišnična higiena:** higiena rok, aktivno iskanje nosilcev, ukrepi kontaktne izolacije, razkuževanje opreme in pripomočkov, ki pridejo v stik s koloniziranim bolnikom
  - **zmanjševanje možnost vnosa novih rezistenčnih determinant** iz bakterij okoljskega in živalskega izvora.

mlajša bolnica iz Slovenije
Prometna nesreča v Srbiji, 14 dni hospitalizirana v UKC Beograd → premestitev v UKCL

Izolat	K. pneumoniae	P. stuartii	P.mirabilis	E.raffinosus	E.faecalis	E.faecium	S.aureus	A.baumannii
	- CRE	- CRE	- CRE	- VRE	- VRE	- VRE	- MRSA	- CRAb
oksacilin							R	
amoksicilin/klav.k.	R	R	R				R	
ampicilin/sulbakt.								R
piperacilin/tazob.	R	R	R					R
ceftazidim/cefotaksim	R	R	R					R
cefepim	R	R	R					
ertapenem	R	R	R					
imipenem	R	R	R					R
meropenem	R	R	R					
ciprofloksacin	R	R	R	S	R	R	R	R
amikacin	S	R	S					R
gentamicin	R	R	S				R	R
trimetoprim/sulfam.	R	R	R				S	
teikoplanin				I	R	R	S	
vankomicin				R	R	R	S	
kolistin	S	R	R					S
daptomicin							R	
linezolid				S	S	S	S	
rifampin				S	R	R	R	
tigeciklin	I	R	R					